Developing biologics to treat gut diseases
Engineering Biologics for treatment of enteric diseases
['FUNDING_R01'] · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · NIH-10991424
This study is working on a new way to create oral treatments for gut issues like diarrhea and inflammatory bowel disease, aiming to make them safer and more effective by focusing the medicine right where it's needed in the stomach.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR (nih funded) |
| Locations | 1 site (COLLEGE STATION, UNITED STATES) |
| Trial ID | NIH-10991424 on ClinicalTrials.gov |
What this research studies
This research focuses on creating biologics that can be delivered orally to treat enteric diseases like acute diarrhea and inflammatory bowel disease. The approach aims to overcome the challenges of traditional biologics that are administered systemically, which can lead to side effects and reduced effectiveness due to the unique environment of the gastrointestinal tract. By engineering a stable protein scaffold and a specialized delivery platform, the research seeks to enhance the local concentration of the treatment in the gut while minimizing systemic exposure. This could lead to more effective and safer treatment options for patients suffering from these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from enteric diseases such as acute diarrhea or inflammatory bowel disease.
Not a fit: Patients with enteric diseases that do not respond to biologic treatments or those with conditions unrelated to the gastrointestinal tract may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective and safer treatments for enteric diseases with fewer side effects.
How similar studies have performed: Other research has shown promise in developing localized biologic treatments for gastrointestinal conditions, indicating that this approach may be viable.
Where this research is happening
COLLEGE STATION, UNITED STATES
- TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR — COLLEGE STATION, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, ZHILEI — TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- Study coordinator: CHEN, ZHILEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.